← Back to Search

Antimalarial

Hydrocholoroquine Pre-exposure prophylaxis for Coronavirus (HERO Trial)

Phase 3
Waitlist Available
Led By Bradley A Connor, MD
Research Sponsored by GeoSentinel Foundation
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 90 days
Awards & highlights
All Individual Drugs Already Approved
Approved for 10 Other Conditions
Pivotal Trial

Summary

This trial will test if taking hydroxychloroquine (HCQ) once a day can prevent COVID-19 infection in hospital workers. 374 workers will be given either HCQ or a placebo and followed for 90 days. The trial will compare the number of infected workers in each group.

Eligible Conditions
  • Coronavirus
  • Prophylaxis
  • Health Care Worker
  • Hydroxychloroquine

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~90 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 90 days for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Cumulative Incidence of COVID-19 Infection
Secondary study objectives
Adverse events incidence
Days hospitalized attributed to COVID-19
Days of work lost
+3 more
Other study objectives
Number of participants with severity markers of host immune and endothelial activation
Proportion of HCW with plasma able to neutralize SARS-CoV-2 virus

Awards & Highlights

All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Approved for 10 Other Conditions
This treatment demonstrated efficacy for 10 other conditions.
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Hydrocholoroquine Pre-exposure prophylaxisExperimental Treatment1 Intervention
HCQ will be administered as 400mg orally once for 60 days.
Group II: PlaceboPlacebo Group1 Intervention
Placebo will be administered as 400mg orally once for 60 days.

Find a Location

Who is running the clinical trial?

GeoSentinel FoundationLead Sponsor
Bradley A Connor, MDPrincipal InvestigatorDr. Bradley A. Connor
~68 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top